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Haiyan Guo1*, Ying Chen2,3, Xiaobo Hu1, Guanxiang Qian4, Shengfang Ge3,4 and Jianjun Zhang2*Abstract
Background: The Toll-like receptor 2 (TLR2)-driven tissue response may promote neoangiogenesis and tumour
growth by mechanisms that are poorly understood.
Methods: We investigated the expression levels of TLR2 and associated-miRNAs in colorectal carcinoma (CRC)
tissues and cell lines using real-time PCR, northern blotting and western blotting. Survival curver was generated by
Log-Rank test and the role of TLR2 signalling in tumour invasion and migration was determined by transwell
analysis kits.
Results: We observed that the tissues from CRC patients express relatively high levels of TLR2. Targeting TLR2
markedly reduces the invasion and migration of CRC cells. We also found that miR-143, a putative tumour
suppressor that is down-regulated in CRC tissues, reduces the invasion and migration of CRC cells primarily via
TLR2. Utilising a xenograft mouse model, we demonstrated that re-expression of miR-143 inhibits CRC cell
colonisation in vivo.
Conclusion: miR-143 blocks the TLR2 signalling pathway in human CRC cells. This knowledge may pave the way
for new clinical applications utilising miR-143 mimics in the treatment of patients with CRC.
Keywords: miR-143, Toll-like receptor 2, Colorectal carcinoma, Invasion, MigrationIntroduction
Colorectal carcinoma (CRC) is a commonly diagnosed
cancer in males and females. It is estimated that over 1.2
million new cancer diagnoses and 608,700 deaths from
colorectal cancer occurred in 2008 [1]. Tumour metastasis
is the most common cause of death in patients with
CRC, but there are no effective therapies that target the
development and progression of metastasis [2]. One
therapeutic strategy against tumour invasion and migra-
tion of recent interest is immunotherapy using agonists
of Toll-like receptors (TLRs) as adjuvants [3-5].
The TLRs are a family of receptors consisting of highly
conserved molecules, that recognise the pathogen-* Correspondence: sxguohaiyan@126.com; zjjshuobo@163.com
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reproduction in any medium, provided the orassociated molecular patterns (PAMP) of microorgan-
isms and viruses and play critical roles in the innate
immune response and subsequent induction of the adap-
tive immune response [6-8]. Moreover, TLRs induce
chronic inflammation after being activated by damage-
associated molecular patterns (DAMPs) released from in-
jured tissue or tumour tissue [9,10]. Activation of TLR
signalling in the steady state maintains tissue architecture.
However, in the presence of the deregulated inflammation
that occurs during tumourigenesis, the TLR-driven tissue
response may promote neoangiogenesis and tumour
growth by poorly defined mechanisms [11]. Recent studies
have demonstrated that engagement of TLRs increases
tumour growth and tumour immune evasion and induces
resistance to apoptosis and chemoresistance in some
tumour cells [12,13], implying the possibility of TLR-
targeted cancer therapy. In lung cancer, it has been
shown that engagement of TLR4 and TLR9 induces
apoptosis in cancer cells [14]. In ovarian cancer cells, it. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in increased growth and chemoresistance [13]. These find-
ings demonstrate that different tumours express different
functional TLRs, and the effects of TLR signalling in can-
cer cells may vary according to cancer cell type.
A growing body of evidence suggests that the Toll-like
receptor 2 (TLR2) in the intestinal epithelium of patients
with CRC or inflammatory bowel disease is up-regulated
in comparison with healthy individuals [15-17]. In gen-
eral, stimulation of TLR2 induces a TH2, Treg, or TH17
type of immune response [18,19]. It is clear that TLR2
has a unique position in the regulation of tumour toler-
ance, cancer progression and metastasis [20].
In this study, we identified a putative tumour suppres-
sor miRNA, miR-143, that is frequently down-regulated
in CRC. We demonstrated that miR-143 can directly
regulate TLR2 expression in CRC cells. High levels of
miR-143 can inhibit tumour invasion and migration
in vitro and in vivo by reducing TLR2 activity. Our study
provides strong evidence that TLR2 may be targeted by
miR-143 to overcome chronic inflammation and down-
regulate tumour invasion and migration.
Materials and methods
Ethics statement and human colorectal carcinoma tissues
The specimens were collected from patients who under-
went surgery at the Shanghai Renji Hospital between
January 2004 and January 2010. The mean follow-up time
was 92 months (from 41 to 122 months). The protocol was
approved by the Shanghai Jiao Tong University School of
Medicine Clinical Research Ethics Committee, and the
research was performed according to the 1975 Helsinki
Declaration provisions. Written informed consent was
obtained from all participants involved in the study.
Cell lines
The colorectal carcinoma cell lines, including LS174T
(ATCC number: CL-188™, Dukes’ type B cells), SW480
(ATCC Number: CCL-228™, Dukes’ type B cells), SW620
(ATCC Number: CCL-227™, Dukes’ type C cells) and
HCT116 (ATCC number: CCL-247, Dukes’ type D cells),
were purchased from the Cell Bank of Type Culture
Collection of the Shanghai Institute of Cell Biology,
Chinese Academy of Sciences. These colorectal carcinoma
cell lines were maintained in RPMI 1640 containing
10% foetal calf serum. Cultures were incubated at 37°C
in standard tissue culture incubators.
Real-time PCR
Total RNA was extracted from cells using TRIzol
Reagent (Life Technologies, Gaithersburg, MD, USA).
Real-time PCR analyses were performed to detect TLR2
mRNA expression using SYBR Premix Ex Taq (TaKaRa,
Dalian, China), and GAPDH was used as an internalcontrol. Real-time PCR was performed under the follow-
ing conditions: 95°C 10 m, 1 cycle; 95°C 10 s, 55°C 34 s,
40 cycles. The PCR primers were TLR2 forward 5′
GATGC CTACT GGGTG GAG 3′, TLR2 reverse 5′
AAAGA CGGAA ATGGG AGA 3′; GAPDH forward:
5′ TGGGG AAGGT GAAGG TCGG 3′ and GAPDH
reverse: 5′ CTGGA AGATG GTGAT GGGA 3′.
The MiRcute miRNA qPCR detection kit (TIANGEN,
Beijing, China) was used to quantify the expression levels
of mature miR-143 according to the protocol provided,
and GAPDH was used as an internal control. The primer
sequence used was the miR-143 specific primer 5′ TGA
GA TGAAG CACTG TAGCT C 3′. Real-time PCR was
performed under the following conditions: 95°C 1 m,
1 cycle; 95°C 10 s, 65°C 40 s, 40 cycles.
For all results obtained by real-time PCR methods, we
used the delta delta CT method to calculate the fold
change in gene expression between different groups.
We used a housekeeping gene (GAPDH) for endogenous
normalisation. The amount of target (TLR2/miR-143),
normalised to the endogenous housekeeping gene GAPDH
and relative to a reference sample, is given by the follow-
ing equation: amount of target =2-△△CT.
Vector constructs
The full length wild type 3′UTR (UTR-WT) of the
TLR2 mRNA containing the putative miR-143 binding
sites was amplified by PCR and cloned into the Xba1 site
of the pGL3 control vector (Promega, Madison, WI,
USA). The amplified PCR primers used were TLR2
UTR-WT forward: 5′ GATGC CTACT GGGTG GAG
3′, and TLR2 UTR-WT reverse 5′ AATAC TTTGC
CTTGT TGC 3′. The mutant 3′UTR of TLR2 (UTR-
MUT), which carried a mutation in the complementary
site for the seed region of miR-143, was generated from
the UTR-WT plasmid by overlap-extension PCR. The
TLR2 transcript with a deletion mutation for 3′UTR
(TLR2) was amplified and cloned into the pcDNA3.0
vector. The amplified PCR primers used were TLR2
CDS forward: 5′ CTGGA CAATG CCACA TAC 3′, and
TLR2CDS reverse: 5′AAGATCCCAACTAGACAAA 3′.
Oligonucleotide transfection
S transfectants over-expressing miR-143 were generated
by lentiviral transduction using a pMIRNA1 plasmid
carrying miR-143 (System Biosciences, Mountain View,
CA). Mimics and inhibitors of miR-143 were purchased
from Dharmacon (Lafayette, CO, US). Transient trans-
fections of miR-143 mimics/inhibitors in cancer cells
were performed using Lipofectamine™ 2000 (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s proto-
col. The final concentration of miR-143 mimics/inhibitors
in the transfection system was 100 nM. As a positive con-
trol, the mature sequence of has-miR-19a is 5′-UGUGC
Guo et al. Molecular Cancer 2013, 12:77 Page 3 of 10
http://www.molecular-cancer.com/content/12/1/77AAAUC UAUGC AAAAC UGA-3′. The final concentra-
tion of miR-19a mimics in the transfection system was
100 nM.
For the TLR2 knockdown, the sequences of the siRNA
were: 5′-GGGCA GUCUU GAACA UUUAU U-3′ and
5′-UAAAU GUUCA AGACU GCCCU U-3′. All of
the RNAi oligoribonucleotides were purchased from
Genepharma (Shanghai, China). Transfection was per-
formed with Lipofectamine™ 2000 following the manufac-
turer’s protocol. A final concentration of 100 nM of TLR2
siRNA and the negative controls was used for each trans-
fection. Twenty-four hours after transfection, the bio-
logical behaviour of the cancer cells was observed.
Luciferase assay
SW620 cells were seeded in 24-well plates and co-
transfected with 100 nM of miR-143 mimics, 100 ng/ml
UTR-WT or UTR-MUT luciferase reporter construct,
and 10 ng/ml pRL-CMV Renilla luciferase reporter using
lipofectamine 2000. Cells were collected 24 h after trans-
fection, and luciferase activity was measured with a
dual-luciferase reporter assay (Promega, Madison, WI,
USA). The luciferase activity was normalised to the
Renilla luciferase activity.
Northern blotting
We extracted RNA with the mirVana™ miRNA Isolation
kit (Ambion, Austin, TX) using the microRNA enrichment
protocol. Mature miR-143 was measured by northern
blotting using a Northern Max-Gly Kit (Ambion, Austin,
TX). Briefly, after RNA electrophoresis, the transferred
membrane was prehybridised with ULTRAhyb and de-
tected with a miR-143-specific oligonucleotide probe (5′
GAGCT ACTGT GCTTC ATCTC A 3′) labelled with
digoxigenin-ddUTP using a DIG Oligonucleotide 3′-
End Labeling Kit (Roche Diagnostics, Indianapolis, IN).
U2snRNA was used as an internal control. The U2snRNA-
specific oligonucleotide probe used was 5′ TCGGA
TAGAG GACGT ATCAG ATATT AAA 3′.
Western blot
Proteins were separated on a 10% SDS-PAGE gel and
then transferred to a PVDF membrane. The membrane
was incubated with a rabbit TLR2 polyclonal antibody
(1:1000, Proteintech, Chicago, IL, USA). The secondary
antibodies were labelled with IRDyes. The signals were
observed using an Odyssey Infrared Imaging System
(LI-COR Biosciences, Lincoln, NE, USA).
Growth assay
The proliferation assay was performed with the Cell
Counting Kit-8 (Dojindo, Kumamoto, Japan) according
to the manufacturer’s instructions. Before the addition of
CCK-8, the cells were washed with warm culture mediaby spinning the plate at 500 rpm for 3 m and then
discarding the supernatant.
Cell migration and invasion assays
Transwell migration and invasion assays were performed
as described previously [21]. The cell invasion assay was
performed with matrigel (BD Biosciences, Sparks, MD)
coated on the upper surface of a Transwell chamber
(Corning, Lowell, MA). The cell migration assay was
performed in a Transwell chamber untreated with ma-
trigel. The cells that had migrated or invaded through
the membrane were fixed with 4% paraformaldehyde
and stained with Coomassie brilliant blue methanol.
Photographs of 3 randomly selected fields of the fixed
cells were taken, and the cells were counted.
Mouse experiments
Aliquots of 1 ×106 stable miR-143 or miR-NC over-
expressing SW620 cells were injected into immunodefi-
cient mice and evaluated for lung colonisation capacity
in tail-vein assays. Lung colonisation was measured using
bioluminescence at 1, 2, 3, 4, 5 and 6 weeks after injection.
Statistical analyses
The data are shown as the mean ± SD. Multiple group
comparisons were performed by one-way ANOVA, and
survival curver was generated by Log-Rank test followed
by the SPSS procedure for comparison of means.
A p < 0.05 was considered to be significant.
Results
TLR2 is highly expressed in human CRC tissues
and cell lines
To determine the potential roles of TLRs in the regula-
tion of tumourigenesis, we first examined the expression
of TLRs in CRC. Using real-time PCR and immunohis-
tochemistry analysis, we analysed TLR2 expression in 39
paired samples (tumour and adjacent noncancerous
tissues from the same patient) and found that TLR2
expression is significantly up-regulated in CRC tissues
(Figure 1A and Additional file 1: Figure S1; ***p < 0.001).
We observed that TLR2 expression was significantly
up-regulated in 4 CRC cell lines compared with normal
epithelial tissues (Figure 1B; ***p < 0.001). Additionally, we
detected higher TLR2 expression in poorly differentiated
tumour cells (SW620 and HCT116) compared with
well-differentiated tumour cells (SW480 and LS174T).
The TLR2 expression profile of human CRC tissues
revealed that high levels of TLR2 correlated with
more advanced pathology grades (1, 2, 3) and lymph
node metastasis (N0, N1, N2) (Figures 1C and 1D;
***p < 0.001; **p < 0.01; *p < 0.05), suggesting an associ-
ation between TLR2 expression and tumour progres-
sion. Accordingly, TLR2 levels above the median
Figure 1 High TLR2 levels are associated with malignant
transformation and lower overall survival in CRC patients.
(A) Expression of TLR2 in 39 pairs of tumour samples and matched
adjacent noncancerous tissues was measured by real-time PCR. (B)
Expression of TLR2 was determined by real-time PCR in 3 normal colon
epithelial cells and 4 CRC cell lines (SW480, LS174T, SW620, and HCT116).
(C) Expression of TLR2 was determined in 79 CRC tissues (grade1 n = 18;
grade2 n = 20; grade3 n = 41) by real-time PCR. The statistical method
analysed the correlation between the expression of TLR2 and tumour
pathological grade. (D) Expression of TLR2 was checked in 79 CRC tissues
(N0 n = 28; N1 n = 31; N2 n = 20) by real-time PCR. The statistical method
analysed the correlation between the expression of TLR2 and tumour
lymph node metastasis. (E) Lower overall survival of patients with high
TLR2 levels (above median; n= 37) compared to patients with low TLR2
levels (belowmedian; n= 42). (***p < 0.001; **p < 0.01; *p < 0.05).
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CRC (Figure 1E; p = 0.0025). The characteristics of the
patients with colorectal carcinoma are listed in Table 1.
TLR2 mediates the capacity for invasion and migration
in CRC cells
We examined the role of TLR2 in CRC cell invasion,
migration, and growth. To examine the down-regulatingeffect of siRNA on TLR2 expression, we performed a
qRT-PCR analysis (Figure 2A and Additional file 2: Figure
S2A; left panel) and a western blot analysis (Figure 2A and
Additional file 2: Figure S2B; right panel) 48 h after
transfecting SW620 and HCT116 cells with siRNA for
TLR2 (siTLR2). As shown in Figure 2A, compared to the
negative control group (siRNA-NC), ectopic expression of
siTLR2 significantly decreased the expression of TLR2.
Cell migration and invasion are crucial steps in the
physiopathology of many diseases, including cancer. The
migration and invasion of tumour cells into surrounding
tissues is a pernicious progression, resulting in the devel-
opment of distant metastases [22]. In comparison with
the negative control (siRNA-NC), TLR2 knockdown sig-
nificantly inhibited the invasive and migratory activities
of SW620 and HCT116 cells (Figures 2C and 2D,
**p < 0.01; *p < 0.05). However, TLR2 knockdown did not
affect the growth of SW620 and HCT116 cells (Figure 2B;
p > 0.05). Transfection with the TLR2 expression vector
(TLR2) significantly increased cell invasion and migration
in normal colon epithelial cells (Additional file 2: Figures
S2C and S2D). Additionally, TLR2 was over-expressed
in several human tumour cell lines, such as gastric car-
cinoma cells and melanoma cells [23,24]. Our results
showed that knockdown of TLR2 markedly reduced the
invasive capacity of highly metastatic cancer cell lines,
including human lung adenocarcinoma A549 cells and
human breast cancer MDA-MB-231 cells (data not shown).
TLR2 expression correlates with miR-143 in CRC tissues
and cells
MicroRNAs (miRNAs) have emerged as important regu-
lators of cell signalling mediators via interfering with
mRNA stability or translation [25,26]. To identify poten-
tial miRNAs that are involved in TLR2 signalling, we
searched for miRNAs targeting TLR2 using microrna.
org (http://www.microrna.org/microrna/getGeneForm.
do), TargetScan (http://www.targetscan.org/), and Mic-
rocosm Targets (http://www.ebi.ac.uk/enright-srv/mic-
rocosm/htdocs/targets/v5/) software. By comparing the
results of the predictive algorithms, we identified miR-101,
miR-143, miR-154, and miR-340 as the candidate TLR2-
targeting miRNAs. The predicted binding of miRNAs
with the 3′UTR of TLR2 is illustrated in Additional file
3: Figure S3D.
We detected the expression of TLR2 and mature miR-
143 in the same clinical samples using real-time PCR
(N = 79). Using nonparametric tests, we found a signifi-
cant inverse correlation between TLR2 expression and
miR-143 expression in CRC tissues (R2 = 0.4486,
p = 0.000 for TLR2 and miR-143) (Figure 3A; Table 1).
We utilised the same tests to determine whether TLR2
is a putative target of miR-101, miR-154, and miR-340
and found no inverse correlation between TLR2 and
Table 1 Characteristics of the 79 colorectal
carcinoma patients
Variables Number (%)
Gender (male/female) 39 (49.4.)/40 (50.6)
Age (mean±SD) 53.4 ± 15.2
Maximum size (<5 cm/≥5 cm) 38 (48.1)/41 (51.9)
Stage (I/II/III/IV) 7 (8.9)/21 (26.6)/32 (40.5)/19 (24.0)
Pathology grade (1/2/3) 18 (22.8)/20 (5.3)/41(51.9)
Lymph nodes (N0/N1/N2) 28 (35.4)/ 31(39.2)/20 (25.3)
Vascular invasion (no/yes) 36 (45.6)/43 (54.4)
Preoperative chemotherapy* (no/yes) 66 (83.5)/13(16.5)
Postoperative chemotherapy* (no/yes) 19 (24.1)/60(75.9)
Mean follow- up time (months) 92 (from 41 to 122).
* Chemotherapy: 5-FU & low-dose Leucovorin (Mayo Clinic regimen/LDLV).
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In addition, we examined the endogenous miR-143 ex-
pression levels by northern blotting in 5 normal colon
epithelial tissues and 4 CRC cells. The expression of
miR-143 was significantly lower in 4 CRC cells with
high TLR2 expression levels (Figure 3B and Additional
file 3: Figure S3A), especially in the poorly differenti-
ated tumour cells SW620 and HCT116, showing that
miR-143 levels are inversely correlated with the levels
of TLR2 expression. The miR-143 profile of human
CRC tissues revealed that low levels of miR-143 are
correlated with more advanced pathology grades (1, 2,
3) and lymph node metastasis (N0, N1, N2) (Figures 3CFigure 2 High TLR2 levels facilitate CRC cell migration and invasion. (
treated with siRNA for TLR2 (siTLR2). (B) Proliferation was detected using a
Migration of SW620 and HCT116 cells treated with siTLR2 was determined
SW620 and HCT116 cells treated with siTLR2 was determined using matrigand 3D; ***p < 0.001; **p < 0.01; *p < 0.05), suggesting
an association between low miR-143 expression and
tumour progression. Additionally, miR-143 levels above
the median correlate with a higher overall survival of
patients with CRC (p = 0.0018) (Figure 3E).
miR-143 directly targets TLR2 and reverses the invasive
and migratory phenotype in CRC cells
SW620 and HCT116 cells, which express very little
mature miR-143, were transfected with a miRNA mimic
(miR-143 mimic) and its inhibitor (Anti-miR-143). The
ectopic expression of mature miR-143 was confirmed by
real-time PCR assay. As expected, an approximately 10-
fold increase in mature miR-143 was detected in the
miR-143 mimic transfected cells (Additional file 3: Figure
S3B). In contrast, transfection with the miR-143 inhibitor
(Anti-miR-143) reduced mature miR-143 by almost
70% in SW620 and HCT116 cells (Additional file 3:
Figure S3C).
To examine the down-regulatory effect of miR-143 on
TLR2 expression, we performed a western blot analysis
48 h after transfecting SW620 and HCT116 cells with
the miR-143 mimic (100 nM) or Anti-miR-143 (100
nM). Compared to the negative control group (miR-NC
mimic), ectopic expression of miR-143 significantly de-
creased the expression of TLR2 protein levels (Figures 4A
and Additional file 4: Figure S4A). This inhibition was
abolished by treatment with Anti-miR-143, which is an
antagonist for miR-143 (Figures 4B and Additional file 4:
Figure S4B). Previous studies have reported that the
Toll-like receptor family members TLR3 [27], TLR4 [28],A) Expression of TLR2 was measured in SW620 and HCT116 cells
Cell Counting Kit-8 in SW620 and HCT116 cells treated with siTLR2. (C)
using Transwell chambers untreated with matrigel. (D) Invasion of
el-treated Transwell chambers. (**p < 0.01; *p < 0.05).
Figure 3 Expression levels of TLR2 are inversely correlated with miR-143 in CRC tissues and cell lines. (A) Expression of miR-143 was
determined using real-time PCR in 79 CRC tissue samples, and the correlation of TLR2 expression levels with miR-143 in CRC tissues was evaluated
using nonparametric tests (R2 = 0.4486; p = 0.000). (B) Expression of miR-143 was determined by northern blotting in 5 normal colon epithelial cells
and 4 CRC cell lines (SW480, LS174T, SW620, and HCT116). (C) Expression of miR-143 was determined in 79 CRC tissues (grade1 n = 18; grade2 n = 20;
grade3 n = 41) by real-time PCR. The statistical method analysed the correlation between the expression of miR-143 and tumour pathological grade.
(D) Expression of miR-143 was determined in 79 CRC tissues (N0 n = 28; N1 n = 31; N2 n = 20) by real-time PCR. The statistical method analysed the
correlation between the expression of miR-143 and tumour lymph node metastasis. (E) Higher overall survival of patients with high miR-143 levels
(above median; n = 38) compared to patients with low miR-143 levels (below median; n = 41). (***p < 0.001; **p < 0.01; *p < 0.05).
Figure 4 miR-143 directly targets TLR2. (A) Expression of TLR2, TLR3, TLR4, and TLR5 was measured in SW620 and HCT116 cells transfected with
miR-143. NC is a double-stranded RNA and represents the miRNA mimic negative control. (B) Expression of TLR2 was measured in SW620 and HCT116
cells transfected with Anti-miR-143. NC is a single-stranded RNA and represents the anti-miRNA negative control. (C) The levels of TLR2 mRNA are
negatively regulated by miR-143 in SW620 and HCT116 cells. (D) The sequence alignment of miR-143 with the putative binding site in the 3'UTR of the
TLR2 gene. Reporter assay in SW620 cells transfected with luciferase constructs (UTR-WT or UTR-MUT) (mean ± SD). (E) Inhibition of migration and
invasion of cancer cells by miR-143 was measured using Transwell chambers untreated with matrigel and matrigel-treated Transwell chambers.
(WT: wild type; MUT: mutant; **p < 0.01; ***p < 0.001).
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tissues. Therefore, we examined whether TLR3, TLR4, and
TLR5 are also regulated by miR-143 in human CRC. The
expression of TLR3, TLR4, and TLR5 protein was not af-
fected by miR-143 in SW620 and HCT116 cells (Figures 4A
and Additional file 4: Figure S4A). Using a qRT-PCR
assay, we detected miR-143-induced down-regulation
of TLR2 mRNA expression in SW620 and HCT116 cells,
and a blockage of endogenous miR-143 up-regulated
expression of TLR2 mRNA in SW620 and HCT116 cells
(Figures 4C and Additional file 4: Figure S4C). These
results suggest that miR-143 targets TLR2 by playing a
role in mRNA cleavage.
To further confirm that TLR2 is a direct target of
miR-143, a firefly luciferase reporter assay system was
used. We amplified the complete 3′UTR of TLR2 mRNA
and cloned it into the 3′UTR of the firefly luciferase
gene in the reporter vector UTR-WT. Using the UTR-WT
vector as a template, we constructed a UTR-MUT vector
containing the 3′UTR of TLR2 with point mutations, as
shown in Figure 4D. In addition, miR-19a was used as a
positive control, as it has been reported to target TLR2
in Rheumatoid Fibroblast-like Synoviocytes [30]. The
UTR-WT or UTR-MUT vector was co-transfected with
miR-143 mimic (miR-143), miR-19a mimic (miR-19a)
or miRNA mimic control (miR-NC) into SW620 cells.
As expected, co-transfection with miR-19a dramatically
attenuated UTR-WT luciferase activity. Interestingly, the
UTR-WT luciferase activity in miR-143 co-transfected
SW620 cells was significantly lower than in the cells that
were co-transfected with the miR-NC, whereas mutation
of the miR-143 recognition site rescued the luciferase
activity (Figure 4D). These results collectively suggest
a direct and specific inhibition of the 3′UTR of TLR2
by miR-143 in CRC cells.
TLR2 has been shown to promote invasion and migra-
tion in CRC cells (Figures 2C, 2D, Additional file 2:
Figure S2C and S2D). This finding suggests that re-
expression of miR-143 may lead to a reversal of the in-
vasive and migratory phenotypes in CRC cells. To test
our hypothesis, the effect of ectopic miR-143 expres-
sion on cell invasion and migration was investigated in
SW620 and HCT116 cells. Transfection with miR-143
significantly decreased cell invasion and migration in
SW620 cells and HCT116 cells (Figure 4E). Repression
of TLR2 by miR-143 can partially recapitulate the re-
sults of silencing TLR2 using RNA interference in
SW620 and HCT116 cells (Figures 2C and 2D). In-
versely, miR-143 knockdown significantly increased the
invasive and migratory activities of normal colon epi-
thelial cells (Additional file 4: Figures S4D and S4E).
These results indicate that re-expression of miR-143
dramatically decreases cell invasion and migration in
TLR2-expressing CRC cells.TLR2 mediates the miR-143-induced resistance to
invasion and migration in vitro and in vivo
To determine whether TLR2 is the critical mediator of
the role of miR-143 in cellular invasion and migration,
we constructed a TLR2 transcript with a 3′UTR deletion
mutation (TLR2). First, we performed a western blot
analysis 48 h after transfecting the TLR2 expression
vector with the 3′UTR deletion mutation (TLR2) into
SW620 (Figure 5A and Additional file 5: Figure S5A)
and HCT116 cells (Figures 5C and Additional file 5:
Figure S5B). As shown in the figures, compared to the
negative control group (pcDNA3.0), ectopic expression
of TLR2 significantly increased the expression of TLR2.
Expression of the artificial TLR2 transcript (TLR2)
apparently promoted the invasion and migration of co-
lorectal carcinoma cells. Importantly, re-expression of
TLR2 abolished the miR-143-induced inhibition of cell
invasion and migration (Figures 5B and 5D), indicating
that TLR2 is a critical mediator of the anti-invasive and
anti-migration effects of miR-143 in human CRC cells.
To determine the role of endogenous miR-143 in
metastatic progression, 1 ×106 stable miR-143 or miR-
NC over-expressing SW620 cells were injected into im-
munodeficient mice and evaluated for lung colonisation
capacity using tail-vein assays. In Figure 5E, lung colon-
isation was measured using bioluminescence at 1, 2, 3, 4,
5 and 6 weeks after injection. As indicated, miR-143
over-expression in SW620 cells significantly decreased
lung metastatic colonisation. Additionally, lung biolumin-
escence was imaged 24 h post miR-143 over-expressing
SW620 cells injection (Figure 5F). We detected lower
photon flux intensity in SW620 cells treated with miR-
143. These results may support the role of miR-143 in
inhibiting the early colonisation of colorectal carcinoma
cells at the lung.
Discussion
Recently, TLR signalling pathways have been shown to
be involved in tumour growth and immune evasion.
Various microbial products have been used as adjuvants
due to their ability to enhance tumour immunotherapy
by stimulating TLR signalling and activation of both in-
nate and adaptive immune responses [31]. However, the
results of studies using TLR agonists as adjuvants in
cancer treatments are contradictory and require further
investigation, as the use of TLR ligands in cancer im-
munotherapy could turn out to be a double-edged sword
[20]. Because our studies of elevated TLR2 expression in
CRC do not support the use of agonists for treatment, it
is important to study TLR expression in patients to
better predict possible chemotherapeutic benefits.
TLR2, a unique member of the TLR family localised to
the plasma membrane, recognises lipid and protein
ligands and mediates both Th1 and Th2 immune re-
Figure 5 TLR2 modulation accounts for the antimetastatic effect of miR-143. (A) Western blot showing TLR2 expression in SW620 cells 48 h
after transfection with the artificial TLR2 expression vector (TLR2). (B) The effects of miR-143, TLR2, and miR-143 combined with TLR2 on the migration
and invasion of SW620 cells. (C) Western blot showing TLR2 translation in HCT116 cells 48 hours after transfection with TLR2. (D) The effects of
miR-143, TLR2, and miR-143 combined with TLR2 on the migration and invasion of HCT116 cells. (E) Aliquots of 1 ×106 stable miR-143 or miR-NC
over-expressing SW620 cells were injected into immunodeficient mice and evaluated for lung colonisation capacity in tail-vein assays. Lung
colonisation was measured using bioluminescence at 1, 2, 3, 4, 5 and 6 weeks after injection. (F) The bar graph represents 24 hour time-point
measurements of the normalised photon flux from animals injected with SW620 cells. Representative images are shown. n = 5 for each group; error
bars indicate SD.
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pro-inflammatory cytokines that enhance tumour inva-
sion and migration [32]. Elevated expression of TLR2 in
our cancer patient group could be associated with inva-
sive or migratory activity. In a series of in vitro experi-
ments, TLR-2 was identified as a critical receptor for
mediating inflammation via activation of the intracellular
signalling pathway that results in the translocation of
NF-κB and the secretion of TNF-α and IL-1β [33]. In
both tumour and host cells, TLR2 plays a crucial role in
the establishment of a tumour-induced immunosuppres-
sive environment. Targeting TLR2 leads, directly or indir-
ectly, to the induction of strong anti-tumour immunity,
which places TLR2 in a unique position as a promising
target for cancer immunotherapy. However, the cause
of TLR2 overexpression in human cancers has not been
elucidated. The results presented here are the first line
of evidence in support of the hypothesis that over-
expression of TLR2 in CRC may result from under-
expression of a specific miRNA molecule, miR-143;
thus, our results demonstrate a new regulatory mech-
anism for CRC cell invasion and migration.
Aberrant miRNA expression profiles in cancer have
been reported by several groups [34,35]. However, the
pathological roles and molecular mechanisms of theaberrantly expressed miRNAs in CRC are poorly under-
stood. miR-143 is particularly interesting because it
possesses tumour suppressive activity and its expression
is substantially reduced in several cancer types, especially
in CRC [36,37]. Consistent with previous reports, our
results reveal that miR-143 is under-expressed in most
CRC samples. These results imply that miR-143 might
serve as a novel diagnostic and therapeutic target for CRC.
Many studies have identified several miR-143 targets,
including MDM2 [38], KRAS [39], and HK2 [40]. Ricci-
Vitiani et al. found that restoring miR-143 and miR-145 in
colon cancer cells decreases proliferation, migration and
chemoresistance. They also identified CD44, KLF5, and
BRAF as proteins targeted by miR-143 and miR-145 [40].
As with many other miRNAs, the biological information
available for miR-143 is largely limited to expression
analysis. One significant obstacle that has limited the
interpretation of many miRNA-profiling studies is that it
is relatively difficult to identify specific miRNA targets.
In this study, overexpression of TLR2 was identified
in a large-scale study of human CRC tissues. We also
detected the pro-invasive and pro-migratory effects of
TLR2 in CRC cell lines. The results indicate that TLR2
may function as an oncogene. To further investigate the
causes of high TLR2 expression, we found a significant
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143 expression in CRC tissues using bioinformatics me-
thods and nonparametric tests. These results indicate that
the expression of TLR2 may be regulated by miR-143.
For further study of the mechanisms, we used a dual
luciferase report assay system to identify the functional
binding site for miR-143 in TLR2 mRNA. We identified
TLR2 as a novel target of miR-143 in CRC cells.
Next, we demonstrated that restoration of high miR-143
expression levels in CRC cells (SW620 and HCT116) is
associated with decreased TLR2 expression. Considering
the function of TLR2 in a pro-invasive and pro-migratory
phenotype, we hypothesised that miR-143 may have the
opposite function. As expected, miR-143 was able to
reduce cancer cell invasion and migration. In animal
experiments, miR-143 over-expression in SW620 cells
significantly decreased lung metastatic colonisation.
We demonstrated both in vivo and in vitro that miR-143
causes TLR2 down-regulation and subsequently inhibits
cancer cell invasion and migration.
It was also important to note that miR-143 was more
effective than siRNA (siTLR2) in inhibiting SW620 and
HCT116 cell invasion and migration (Figures 2C, 2D,
and 4E), despite the finding that the down-regulation of
TLR2 translation by miR-143 was not more effective
than siRNA (siTLR2) (Figures 2A and 4A). These find-
ings suggest that other miR-143 targets may also play
an important role in inhibiting cellular invasion and
migration in CRC cells, such as DNMT3A [41], CD44,
KLF5, KRAS and BRAF [40]. In addition, restoring
miR-143 in colon cancer cells could inhibit proliferation
[40]. However, TLR2 knockdown did not affect the growth
of colorectal carcinoma cells (Figure 2B). These findings
suggest that TLR2 is a novel member of numerous targets
for miR-143 and that different targets can mediate the
specific effects of miR-143.
In summary, our results show that miR-143 and TLR2
form a novel regulatory pathway that controls CRC cell
invasion and migration. Deciphering this mechanism is
an important step towards unravelling the regulatory
network that underlies tumourigenesis, thereby helping
us realise the potential of miRNA in cancer treatment.
Additionally, using TLR agonists as adjuvants in cancer
treatment appears contradictory and requires further
investigation.Additional files
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